Mar 14, 2023 / 05:35PM GMT
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon. Welcome to Barclays Global Healthcare Conference in Miami. Just e-mail me if you have any questions that need addressed. My name is Peter Lawson. I'm one of the SMID-cap biotech analyst at Barclays. I'm really delighted to have on stage with us the management team from Exelixis, Peter Lamb, Chief Scientific Officer; and Andrew Peters, Chief of Strategy. So thank you so much today for your time.
Questions and Answers:
Peter Richard Lawson - Barclays Bank PLC, Research Division - Research AnalystAnd I guess maybe the first question just around the cabozantinib franchise. It's been a fantastic growth engine cash generator for the company, just like -- kind of the puts and pulls -- pushes and pulls we should think about for '23 and the priorities around cabozantinib and then we kind of -- so I'll ask other questions around the deeper in the franchise.
Peter Lamb - Exelixis, Inc. - Executive VP of Scientific Strategy
Yes,